NRXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuraxis Inc (NRXS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock shows bullish technical indicators, positive analyst sentiment, and a significant catalyst in the form of expanded national coverage for its product. While financials show some weaknesses, the revenue growth and increased net income are promising for long-term growth.
The stock is showing bullish momentum with MACD above 0 and positively contracting, RSI in the neutral zone at 60.781, and moving averages indicating an upward trend (SMA_5 > SMA_20 > SMA_200). Key support is at 4.853, and resistance levels are at 6.19 and 6.603, suggesting room for upward movement.
The company has expanded national coverage for its IBStim product, adding 45M lives and unlocking significant pediatric opportunities. Analyst Craig-Hallum raised the price target to $8, reflecting confidence in the company's growth potential.
No significant negative catalysts identified. However, financial metrics such as negative net income and declining EPS and gross margin could be a concern for some investors.
In Q3 2025, revenue increased by 21.72% YoY to $811,414, and net income improved by 28.97% YoY to -$2,321,503. However, EPS dropped by -4.00% YoY to -0.24, and gross margin declined slightly by -2.50% YoY to 83.3%.
Craig-Hallum maintains a Buy rating and raised the price target from $7 to $8, citing the company's expanded national coverage and its potential to unlock significant opportunities in the pediatric market.
